About FOXO4-DRI

FOXO4-DRI (sometimes Proxofim) is a synthetic D-retro-inverso peptide derived from the FOXO4 transcription factor. Its mechanism targets the p53-FOXO4 interaction that keeps senescent cells alive — by disrupting this interaction, FOXO4-DRI selectively induces apoptosis in senescent cells while sparing healthy cells. It’s a senolytic, the first peptide-based compound to show this effect in a published animal-model study (de Keizer lab, 2017).

This is one of the most experimental compounds in the library. Human safety and efficacy data is essentially absent — published research is animal-model only. Anyone working with FOXO4-DRI for research purposes is operating well outside established clinical literature. Treat findings, dosing, and protocols with appropriate caution.

Dosing observed in research literature

Application	Dose range	Frequency	Notes
Animal-model published research	5 mg/kg	3 doses over 1 week	De Keizer 2017 mouse protocol
Conservative human research	1.5 mg total	3 doses over 1 week	Extrapolation from mouse — not clinically validated
Continued cycle	Single 1.5 mg dose	Every 4–8 weeks	Maintenance pattern in informal protocols

There is no clinical trial-derived dose for FOXO4-DRI in humans. The dosing referenced in this table is derived from animal models and informal community protocols — not from published human safety studies.

Typical reconstitution protocols

FOXO4-DRI typically ships as a 5 mg or 10 mg lyophilised vial:

Vial size	BAC water	Concentration	1.5 mg draw
5 mg	2 mL	2.5 mg/mL	60 units (U-100)
5 mg	2.5 mL	2 mg/mL	75 units
10 mg	2 mL	5 mg/mL	30 units

Half-life and storage

Plasma half-life for FOXO4-DRI is poorly characterised in published literature — animal studies suggest a short plasma window with longer tissue retention typical of D-retro-inverso peptides (resistant to proteolytic degradation). Storage: lyophilised at 2–8°C refrigerated. Reconstituted: up to 28 days refrigerated. Never freeze a reconstituted vial.

Frequently asked questions

What’s a senolytic?

A compound that selectively kills senescent cells — cells that have stopped dividing but resist apoptosis and contribute to age-related inflammation. The concept is that clearing these cells may reduce age-related pathology. Other senolytics studied in research include dasatinib + quercetin combinations and fisetin.

Is human data available?

Almost none. The published work is animal-model based. Anyone using FOXO4-DRI for human research is essentially in unstudied territory. Conservative dosing and cautious assessment are appropriate.

How is it different from other anti-aging peptides?

Most anti-aging research compounds work by improving cell function (NAD+ pathway, autophagy, telomere maintenance). FOXO4-DRI works by removing cells — specifically senescent cells. The mechanisms are complementary rather than competing.

What injection site is used?

Subcutaneous abdominal is the documented route in extrapolated protocols. Given the experimental nature and limited data, site rotation is sensible but standardised protocols don’t exist.

Related compounds

FOXO4-DRI sits in the specialty research category as the senolytic peptide. Related: NAD+ (NAD+ replenishment — different anti-aging mechanism). For full category overview: Specialty Research Compounds.